NIH Funding Uncertainty Persists Despite Budget Protection

For biomedical and public health researchers at institutions across the United States, funding unpredictability has come to define the past year. Delays in grant dispersal and looming threats to the National Institutes of Health budget, the nation's largest funder of biomedical research, have left many wondering what is next, even though Congress ultimately rejected proposals to cut $18 billion from the NIH budget.

The primary challenge is uncertainty, which makes it harder to plan research projects, retain personnel and manage labs efficiently. Delays and unpredictability increase administrative burden and slow scientific progress, threatening the nation's position as global research leader. Congress's recent decision to protect core federal research funding has added critical stability, yet challenges and uncertainty remain as that money isn't yet making it into the hands of researchers.

The NIH is still months behind on grant review meetings and dispersing money to 2026 grantees. Some researchers have experienced delays at various stages of the NIH funding process, which can extend research timelines and complicate lab operations as well as cause uncertainty and anxiety. One of the issues with federal funding is the uncertainty of when institutions will receive award money, with numerous grants in the NIH review process that would have already been awarded in previous years, but currently there is no knowledge of when the award money is being released.

Compressed timelines may strain labs with multiyear grants, and many programs may be pushed into the next fiscal year. With the number of grant awards dropping, funding is uncertain for the foreseeable future. If an apportionment does arrive, the NIH will need to obligate a large amount of funding before the Sept. 30 deadline.

Even when funding amounts are maintained, securing grants is increasingly difficult. Every grant is carefully scrutinized by multiple expert reviewers, and the vast majority of proposals, even good ones, don't get funded. The number of researchers receiving R01 grants, the oldest and largest NIH grant mechanism, fell from 7,720 in 2024 to 5,885 in 2025. Funding rates also dropped, from 26% to 19% for early-career investigators and from 27% to 20% for established researchers, between 2024 and 2025.

The transition to multiyear funding, where the budget for awards is allocated entirely in the first year, creates additional complications. For example, one medical school received $88.6 million in R01 awards but only has $75.4 million available to use this year due to this funding structure.

Federal grants are foundational to maintaining top research rankings at academic institutions. Nearly half of one university's $1.93 billion in research expenditures come from federal sources, with NIH support making up nearly $400 million. About 75% of that university's NIH funding goes to the School of Medicine and Public Health. Every dollar from the NIH generated $2.56 of economic activity in the 2024 fiscal year.

At a time when global competitors are accelerating their investments in biomedical research, America cannot afford to fall behind. NIH grants have enabled breakthroughs including the first 3-D printed functional brain and use of nanoparticles to correct a gene causing blindness. They're also the biggest part of what supports cancer research at almost every academic institution and are the critical driver of innovation and progress across all kinds of health research.

This pressure is reshaping career expectations in medical science. There used to be this promise that if you were a contributor in your field and you did really great research, you would have some level of comfort, but that's no longer the case. Some disruptions go beyond increasing competition, such as policy changes that forced researchers to immediately halt experiments and identify alternate funding sources to continue their work.